ACADIA Pharmaceuticals Inc (NASDAQ:ACAD)
| 19.92 Delayed Data As of 4:00pm ET |  +0.02 / +0.10%Today’s Change | 15.74 Today|||52-Week Range 41.20 | -33.84% Year-to-Date |
Latest ACAD News | Press Releases
No recent news for ACADIA Pharmaceuticals Inc.
Today’s Trading
| Previous close | 19.90 |
| Today’s open | 19.95 |
| Day’s range | 19.61 - 20.44 |
| Volume | 1,738,371 |
| Average volume (3 months) | 2,320,276 |
| Market cap | $3.2B |
Data as of 4:00pm ET, 04/23/2018
Growth & Valuation
| Earnings growth (last year) | -0.85% |
| Earnings growth (this year) | +22.19% |
| Earnings growth (next 5 years) | -94.00% |
| Revenue growth (last year) | +620.68% |
| P/E ratio | NM |
| Price/Sales | 29.56 |
| Price/Book | 9.40 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| TAROTaro Pharmaceutical ... | +0.38 | +0.38% |
| AKRXAkorn Inc | -6.65 | -33.76% |
| ---- | ||
| MNKMallinckrodt Plc | -0.69 | -5.01% |
Data as of 4:01pm ET, 04/23/2018
Financials
| Next reporting date | May 8, 2018 |
| EPS forecast (this quarter) | -$0.52 |
| Annual revenue (last year) | $124.9M |
| Annual profit (last year) | -$289.4M |
| Net profit margin | -231.71% |
Profile
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Stephen R. Davis |
Senior VP-Strategy & Technology Operations Bob Mischler |
Corporate headquarters San Diego, California |
Forecasts
